Gossamer Bio Inc (NAS:GOSS)
$ 0.701 -0.029 (-3.97%) Market Cap: 158.58 Mil Enterprise Value: 129.80 Mil PE Ratio: 0 PB Ratio: 5.84 GF Score: 37/100

Gossamer Bio, Inc. - Special Call Transcript

Feb 18, 2021 / 04:00PM GMT
Release Date Price: $10.54 (-3.08%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Gossamer Bio GB004 Investor Day Conference Call.

(Operator Instructions) I would now like to hand the conference over to your speaker today, Faheem Hasnain. Please go ahead, sir.

Faheem Hasnain
Gossamer Bio, Inc. - Co-Founder, CEO, President & Chairman

Welcome and thank you to all of you who are joining us today on the webcast. This is a second in a series of 2 webcasts to highlight the promise of what I've been calling priorities 1A and 1B for Gossamer. The 2 clinical assets that are currently marching through their respective proof-of-concept Phase II clinical trial, seralutinib also known as GB002 for the treatment of pulmonary arterial hypertension and GB004 for the treatment of inflammatory bowel disease.

In case you weren't able to join us in December, our seralutinib webcast is archived in the past Events section of our Investor Relations website. Now we've got a great agenda today for our GB004 Investor Day. We're grateful and excited to be joined by 3 of the top

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot